摘要
观察了３８例慢性肾功能衰竭（ＣＲＦ）患者非透析阶段脂质代谢改变，用３－羟－３－甲基辅酶Ａ（ＨＭＧ－ＣｏＡ）还原酶抑制剂普拉固对２０例ＣＲＦ患者进行治疗，观察其对ＣＲＦ脂质代谢及肾功能的影响，并与单纯饮食治疗１８例作对照。结果显示：ＣＲＦ患者具有以Ⅳ型高脂血症为特征的脂质代谢异常，主要表现为ＴＧ增高，并有Ｔｃｈ、ＬＤＬ－Ｃｈ、ＡｐｏＢ升高，ＨＤＬ－Ｃｈ、ＡｐｏＡ／ＡｐｏＢ降低。用普拉固治疗后，脂质代谢紊乱与肾功能都有改善，与治疗前比均有显著差异。对照组治疗后，血脂变化不大，肾功能虽有改善，但除Ｂｕｎ外，Ｓｃｒ、Ｃｃｒ与治疗前比，无显著差异。
A clinical trial was conducted involving 38 patients with chronic renal failure and Scr levels of 407. 1±131. 20μmol/L. to observe the lipid metabolism in CRF and to evaluate the effects of pravachol, a HMGCOA inhibator, on lipid metabolism and renal function in CRF.The patients were divided into two groups: one on pravachol, the other on dietary therapy only. The result showed that lipid abnormalities were present in nondialyzed patients with CRF. The lipid profile was characterized by the hypertriglyceridemia. Increased concentration of TCh, LDL-Ch and decreased of HDL-Ch as well as low ratio of ApoAl/ApoB were observed in some patients. After taking pravachol, these lipid abnormalitins and renal function were ameliorated. It was concluded that pravachol is valuable in treating hyperlipidemia, ameliorating renal function and preventing progression of CRF.
关键词
肾功能衰竭
普拉固
脂质代谢
肾功能
CRF
Pravacholtherapy
Lipid metabolism
Renal fuction.
